About This Fund
Innovestor Life Science Fund is a specialist EUR 90 million early-stage venture capital fund managed by Innovestor Group, a Finnish venture capital firm focused on deep tech and life science investment across the Nordic and Baltic regions. Launched in February 2022 and headquartered in Helsinki, the fund was established by a team of three founding partners with deep scientific and entrepreneurial backgrounds: Milla Koistinaho, an adjunct professor in neurobiology and serial entrepreneur; Pekka Simula, a seasoned chief executive and founder of multiple health-tech startups; and Petri Laine, one of Finland's most experienced venture capital investors. Anchor investors include Tesi (Business Finland Venture Capital) and the Kasvurahastojen Rahasto (KRR IV) fund-of-funds, both managed by Tesi on behalf of the Finnish state.
The fund's investment strategy targets early-stage biotech and digital health companies from pre-seed through Series A in Finland and the broader Nordic and Baltic countries, with particular interest in drug development (rare diseases, neurological conditions, oncology, and cardiovascular), digital health platforms, automation, medtech devices, and AI-powered healthcare applications. Innovestor Life Science Fund invests initial tickets of EUR 250,000 to EUR 3 million per company and targets a portfolio of approximately 20 companies, with a distinctive co-founding model in which the fund actively co-creates approximately half of its portfolio companies alongside academic spinout teams from leading Nordic and Baltic universities. This origination capability differentiates the fund from purely reactive venture investors in the region.
Since 2022, the Innovestor Life Science Fund has deployed capital into 12 groundbreaking drug development and digital health companies, building one of the most active Nordic life science early-stage portfolios. Recent portfolio activity includes co-founding Polku Therapeutics (in partnership with Torrey Pines Investment), Kasvu Therapeutics, and Soihtu DTX — three neurological spinouts from Finnish academic research. The fund benefits from the broader Innovestor Group platform, which manages multiple technology and growth equity funds across Finland and the Nordics, providing portfolio companies with access to a multi-stage investor network and follow-on capital resources.